Cargando…
Synergistic effect of sodium butyrate and oxaliplatin on colorectal cancer
BACKGROUND: Oxaliplatin (OXA) is a chemotherapy agent commonly used in the treatment of colorectal cancer (CRC). Sodium butyrate (NaB) has an antitumor effect. METHODS: In total, 30 patients in stage III who completed 8 cycles of chemotherapy regimens were recruited for this study. The patients were...
Autores principales: | Shuwen, Han, Yangyanqiu, Wang, Jian, Chu, Boyang, Hu, Gong, Chen, Jing, Zhuang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763735/ https://www.ncbi.nlm.nih.gov/pubmed/36512976 http://dx.doi.org/10.1016/j.tranon.2022.101598 |
Ejemplares similares
-
Inhibitory effect of sodium butyrate on colorectal cancer cells and construction of the related molecular network
por: Xi, Yang, et al.
Publicado: (2021) -
Synergistic effects of sodium butyrate and cisplatin against cervical carcinoma in vitro and in vivo
por: Chu, Huijun, et al.
Publicado: (2022) -
Prognostic model based on six PD-1 expression and immune infiltration-associated genes predicts survival in breast cancer
por: Junjun, Shen, et al.
Publicado: (2022) -
Screening of molecular targets and construction of a ceRNA network for oxaliplatin resistance in colorectal cancer
por: Wei, Wu, et al.
Publicado: (2019) -
The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress
por: Chen, WeiQian, et al.
Publicado: (2019)